Literature DB >> 29073323

Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice.

Tessa E H Römkens1,2, Rene Te Morsche1, Wilbert Peters1, David M Burger3, Frank Hoentjen1, Joost P H Drenth1.   

Abstract

Adherence is pivotal but challenging in ulcerative colitis (UC) treatment. Many methods to assess adherence are subjective or have limitations. (Nac-)5-aminosalicylic acid (5-ASA) urinalysis by high-performance liquid chromatography (HPLC) seems feasible and reproducible in healthy volunteers. We performed a prospective study in adult quiescent UC patients to evaluate the feasibility of spot (Nac-)5-ASA urinalysis by HPLC to assess adherence in daily inflammatory bowel disease (IBD) care. Twenty-nine patients (51.7% male, mean age 52 ± 11 years) were included (median FU 9 months) and weekly spot urine samples were collected. We found large variation in spot (Nac-)5-ASA urinary excretion that was unrelated to brand, dosing schedule or dosage of 5-ASA. In conclusion, spot (Nac-)5-ASA urinalysis is not applicable to assess 5-ASA adherence in daily IBD care.
© 2017 The British Pharmacological Society.

Entities:  

Keywords:  HPLC; MMX-mesalazine; adherence; compliance; inflammatory bowel disease

Mesh:

Substances:

Year:  2017        PMID: 29073323      PMCID: PMC5809350          DOI: 10.1111/bcp.13462

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  41 in total

1.  Challenges and innovations in enhancing adherence.

Authors:  Shannon L Mihalko; Gretchen A Brenes; Deborah F Farmer; Jeffrey A Katula; Rajesh Balkrishnan; Deborah J Bowen
Journal:  Control Clin Trials       Date:  2004-10

2.  Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine.

Authors:  C Fischer; K Maier; U Klotz
Journal:  J Chromatogr       Date:  1981-10-09

3.  Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation.

Authors:  Judith E Baars; Veerle J A A Nuij; Bas Oldenburg; Ernst J Kuipers; Christien J van der Woude
Journal:  Inflamm Bowel Dis       Date:  2011-11-08       Impact factor: 5.325

4.  A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study.

Authors:  Anne E Gifford; Anders H Berg; Conor Lahiff; Adam S Cheifetz; Gary Horowitz; Alan C Moss
Journal:  Am J Gastroenterol       Date:  2013-01-08       Impact factor: 10.864

5.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

6.  The burden of comedication among patients with inflammatory bowel disease.

Authors:  Jessie P Buckley; Michael D Kappelman; Jeffery K Allen; Susan A Van Meter; Suzanne F Cook
Journal:  Inflamm Bowel Dis       Date:  2013-12       Impact factor: 5.325

7.  Adherence to topical therapy increases around the time of office visits.

Authors:  Steven R Feldman; Fabian T Camacho; Jennifer Krejci-Manwaring; Christie L Carroll; Rajesh Balkrishnan
Journal:  J Am Acad Dermatol       Date:  2007-05-10       Impact factor: 11.527

Review 8.  Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.

Authors:  W J Sandborn; S B Hanauer
Journal:  Aliment Pharmacol Ther       Date:  2003-01       Impact factor: 8.171

9.  Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study.

Authors:  A Bassi; S Dodd; P Williamson; K Bodger
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

Review 10.  Controversies Revisited: A Systematic Review of the Comorbidity of Depression and Anxiety with Inflammatory Bowel Diseases.

Authors:  Antonina Mikocka-Walus; Simon R Knowles; Laurie Keefer; Lesley Graff
Journal:  Inflamm Bowel Dis       Date:  2016-03       Impact factor: 5.325

View more
  1 in total

1.  Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice.

Authors:  Tessa E H Römkens; Rene Te Morsche; Wilbert Peters; David M Burger; Frank Hoentjen; Joost P H Drenth
Journal:  Br J Clin Pharmacol       Date:  2017-12-06       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.